Evaluation of Patient and Physician Reported Reasons for Switching FVIII Replacement Therapies
Phase of Trial: Phase IV
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Efmoroctocog alfa (Primary) ; Lonoctocog alfa (Primary) ; Octocog alfa (Primary) ; Rurioctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms PARkER
- Sponsors Bayer
- 09 Mar 2018 Status changed from not yet recruiting to recruiting.
- 07 Feb 2018 Planned initiation date changed from 25 Jan 2018 to 14 Feb 2018.
- 29 Jan 2018 New trial record